Substance / Medication

Salmeterol xinafoate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

46 trials linked to this intervention

46
Total Trials
1
Recruiting
25
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
Doull Iolo, Price David, Thomas Mike et al. · Curr Med Res Opin · 2007
PMID: 17519082Meta-Analysis
Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma.
Harrison Lester I, Novak Christopher C, Needham Michael J et al. · J Aerosol Med Pulm Drug Deliv · 2011
PMID: 21671752Observational
Surface energy changes and their relationship with the dispersibility of salmeterol xinafoate powders for inhalation after storage at high RH.
Das Shyamal, Larson Ian, Young Paul et al. · Eur J Pharm Sci · 2009
PMID: 19732829Observational
Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization.
Murnane Darragh, Marriott Christopher, Martin Gary P · Eur J Pharm Biopharm · 2008
PMID: 17981448Observational
Effects of salmeterol xinafoate and fluticasone propionate on immunological activation of human cultured mast cells.
Akabane Hirotomo, Murata Masayuki, Kubota Masafumi et al. · Allergol Int · 2006
PMID: 17130681Observational
Characterization of two polymorphs of salmeterol xinafoate crystallized from supercritical fluids.
Tong H H, Shekunov B Y, York P et al. · Pharm Res · 2001
PMID: 11474791Observational
Inhalable delivery of salmeterol xinafoate-ciclesonide co-amorphous for asthma treatment: prediction, preparation and evaluation.
Bian Yizhen, Liu Xingyu, Xu Qianlin et al. · Int J Pharm · 2025
PMID: 40541627Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Salmeterol xinafoate (substance)
SNOMED CT
108606009
UMLS CUI
C0245531

Clinical Data

This intervention maps to 7 entities in the Healos knowledge graph.

1
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
46
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.